Solanezumab: too late in mild Alzheimer's disease?
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent failures of anti-amyloid agents in phase 3 clinical trials in patients with early-stage, mild, or mild-to-moderate stage Alzheimer disease were semagacestat, bapineuzumab, solanezumab, and the BACE inhibitors lanabecestat, verubecestat, and atabecestat.
“Some of the recent failures of anti-amyloid agents in phase 3 clinical trials in patients with early-stage, mild, or mild-to-moderate stage AD were semagacestat,29 bapineuzumab,30 solanezumab31 and in similar trials of β-secretase inhibitors (BACE) lanabecestat,32 verubecestat,33 and atabecestat.34”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [31]
Cited by
Sorted by citations
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works
Alzheimer’s disease hypothesis and related therapies
Du, X., Wang, X., & Geng, M. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0107-y · Cited by 604 · see citing works
“Even the failed phase III EXPEDITION3 trial of solanezumab (Eli Lilly) still demonstrated better performance in Clinical Dementia Rating Sum of Boxes and beneficial impacts on MiniMental State Examination and Activities of Daily Living [17, 18, 32, 33].”
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568 · see citing works
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330 · see citing works
Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
Villegas, S., Roda, A., Serra-Mir, G., Montoliu-Gaya, L., & Tiessler, L. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.332127 · Cited by 306 · see citing works
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 271 · see citing works
Why do so many clinical trials of therapies for Alzheimer's disease fail?
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228 · see citing works
Polymeric Nanoparticles for Nasal Drug Delivery to the Brain: Relevance to Alzheimer's Disease
Rabiee, N., Ahmadi, S., Afshari, R., Khalaji, S., Rabiee, M., Bagherzadeh, M., Fatahi, Y., Dinarvand, R., Tahriri, M., Tayebi, L., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000076 · Cited by 142 · see citing works
Mild Cognitive Impairment: Diagnosis and Subtypes
Bradfield, N. I. (2021) · Clinical EEG and Neuroscience · doi:10.1177/15500594211042708 · Cited by 111 · see citing works
Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator
Chatterjee, S., Cassel, R., Schneider‐Anthony, A., Mérienne, K., Cosquer, B., Tzeplaeff, L., Sinha, S. H., Kumar, M., Chaturbedy, P., Eswaramoorthy, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708587 · Cited by 95 · see citing works
“We found that H2Bac was globally enriched at CBP enhancers (Fig 7A; LopezAtalaya et al, 2013), as well as H3K27ac, as reported in other tissues (Kim et al, 2010; Jin et al, 2011; Malik et al, 2014; Tie et al, 2014).”
BackgroundMethodIliyasu, M. O., Musa, S. A., Oladele, S. B., & Iliya, A. I. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1081938 · Cited by 101 · see citing works
“, 2016), and solanezumab (Neurology, 2016), failed in recent phase 3 clinical trials.”
BackgroundEFAD transgenic mice as a human APOE relevant preclinical model of Alzheimerʼns disease
Tai, L. M., Balu, D., Avila-Munoz, E., Abdullah, L., Thomas, R., Collins, N., Valencia-Olvera, A. C., & LaDu, M. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076315 · Cited by 93 · see citing works
Drug development for Alzheimer’s disease: Review
Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474361 · Cited by 86 · see citing works
“Unfortunately, in November 2016, Eli Lilly announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial [65].”
BackgroundLa Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74 · see citing works
“…(Bayer et al., 2005; Gilman et al., 2005; Holmes et al., 2008; Salloway et al., 2009; Laskowitz and Kolls, 2010; La Porte et al., 2012; Burstein et al., 2013; Landen et al., 2013; Bouter et al., 2015; Gandy and Sano, 2015; Carlson et al., 2016; Ultsch et al., 2016; The Lancet Neurology, 2017).”
Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study
Landen, J. W., Andreasen, N., Cronenberger, C., Schwartz, P. F., Börjesson‐Hanson, A., Östlund, H., Sattler, C., Binneman, B., & Bednar, M. M. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.003 · Cited by 71 · see citing works
Modulation of γ- and β-secretases as early prevention against Alzheimer's disease
Voytyuk, I., De Strooper, B., & Chávez-Gutiérrez, L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.001 · Cited by 67 · see citing works
Mouchlis, V. D., Melagraki, G., Zacharia, L. C., & Afantitis, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030703 · Cited by 63 · see citing works
Association of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline
Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson, N., Hansson, O., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000013228 · Cited by 47 · see citing works
Bradfield, N. I., & Ames, D. J. (2019) · BJPsych Bulletin · doi:10.1192/bjb.2019.77 · Cited by 39 · see citing works
Increasing phagocytosis of microglia by targeting CD33 with liposomes displaying glycan ligands
Bhattacherjee, A., Daskhan, G. C., Bains, A., Watson, A. E. S., Eskandari‐Sedighi, G., Laurent, C. D. S., Voronova, A., & Macauley, M. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.010 · Cited by 40 · see citing works
Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook
Vāvere, A. L., & Scott, P. J. H. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.05.001 · Cited by 38 · see citing works
Musardo, S., & Marcello, E. E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.06.018 · Cited by 37 · see citing works
Wake, T., Tabuchi, H., Funaki, K., et al. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217002204 · Cited by 36 · see citing works
“In reality, however, amyloid imaging is used in such populations all over the world for the purpose of clinical trials or diagnosis, and no clinical trials have produced promising results on developing anti-amyloid drugs thus far (Editorial, 2017).”
BackgroundImmunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives
Usman, M. B., Bhardwaj, S., Roychoudhury, S., Kumar, D., Alexiou, A. T., Kumar, P., Ambasta, R. K., Prasher, P., Shukla, S. D., Upadhye, V. J., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.52 · Cited by 37 · see citing works
“Although the secondary outcome of this trial slightly favored the drug, solanezumab had no effect on Aβ and tau PET biomarkers; therefore, its development was discontinued (111).”
Hadjichrysanthou, C., Ower, A. K., de Wolf, F., Anderson, R. M., & Initiative, A. D. N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190615 · Cited by 35 · see citing works
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 35 · see citing works
Zhang, S.-S., Gao, Z., Feng, L., & Li, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s483412 · Cited by 38 · see citing works
A refined concept: α-synuclein dysregulation disease
Mochizuki, H., Choong, C., & Masliah, E. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.12.011 · Cited by 34 · see citing works
Brendel, M., Deußing, M., Blume, T., Kaiser, L., Probst, F., Overhoff, F., Peters, F., von Ungern‐Sternberg, B., Ryazanov, S., Leonov, A., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0522-z · Cited by 32 · see citing works
Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site
Takahashi, M., So, T. Y., Chamberlain-Evans, V., Hughes, R., Yam‐Puc, J. C., Kania, K., Ruhle, M., Mann, T., Schuijs, M. J., Coupland, P. G., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ade2094 · Cited by 23 · see citing works
Statin Use and Risk of Cognitive Decline in the ADNI Cohort
Kemp, E. C., Ebner, M. K., Ramanan, S., Godek, T. A., Pugh, E., Bartlett, H. H., McDonald, J. W., Mecca, M. C., van Dyck, C. H., & Mecca, A. P. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.11.003 · Cited by 25 · see citing works
Mishra, K. A., & Sethi, K. K. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400748 · Cited by 21 · see citing works
McGraw, C. M., Ward, C. S., & Samaco, R. C. (2017) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31570 · Cited by 19 · see citing works
Gandy, S., Bartfai, T., Lees, G. V., & Sano, M. C. (2017) · F1000Research · doi:10.12688/f1000research.11140.1 · Cited by 17 · see citing works
Marsool, M. D. M., Prajjwal, P., Reddy, Y. B., Marsool, A. D. M., Lam, J. R., & Nandwana, V. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101547 · Cited by 18 · see citing works
Waragai, M., Ho, G. J., Takamatsu, Y., Shimizu, Y., Sugino, H., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.009 · Cited by 19 · see citing works
“Anon (2017) Solanezumab: too late in mild Alzheimer’s disease?”
BackgroundHan, F., Xu, H., Shen, J.-X., Pan, C., Yu, Z.-H., Chen, J.-J., Zhu, X.-L., Cai, Y.-F., & Lu, Y.-P. (2020) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2020-021 · Cited by 18 · see citing works
New treatment modalities in Alzheimer's disease
Köseoğlu, E. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i14.1764 · Cited by 17 · see citing works
Faisal, M., Aid, J., o‘g‘li, N. B. H., Lee, B., & Hickey, M. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281003 · Cited by 16 · see citing works
Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment
Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037362037250205143911 · Cited by 17 · see citing works
An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β1
Song, G., Yang, H., Shen, N., Pham, P., Brown, B., Lin, X., Hong, Y., Paul, S., Cai, J., Li, X., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200413 · Cited by 15 · see citing works
“Importantly, clinical trials with anti-A (cid:2) “isoform-specific” antibodies have also failed [29].”
Sun, P., Hu, Y., Xing, Q., Deng, W., Ou, Y., Pan, G., Zhong, X., & Hu, W. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00073 · Cited by 15 · see citing works
The sterile controversy on the amyloid cascade hypothesis
Canevelli, M., Bruno, G., & Cesari, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.015 · Cited by 12 · see citing works
Computational Analysis for the Rational Design of Anti-Amyloid Beta (Aβ) Antibodies
Greene, D., Po, T., Pan, J., Tabibian, T., & Luo, R. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b01837 · Cited by 10 · see citing works
Peng, D., Xu, S., Zou, T., Wang, Y., Ouyang, W., Zhang, Y., Dong, C., Li, D., Guo, J., Shen, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03126-9 · Cited by 9 · see citing works
“Unfortunately, these new medications faced unusual rates of clinical failures [12–14]; AD clinical trials accomplished a success rate of only 0.4% from 2002 to 2012 [15].”
BackgroundInfluentialTan, C., Dong, Y., Wang, J., & Yang, X. (2019) · New Journal of Chemistry · doi:10.1039/c9nj00820a · Cited by 8 · see citing works
Treating Alzheimer’s Disease: Focusing on Neurodegenerative Consequences
Sun, M., & Alkon, D. L. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240479 · Cited by 8 · see citing works
Ghazimoradi, M. M., Pour, M. G., Ghoushi, E., Ahmadabadi, H. K., & Rafieian‐Kopaei, M. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230222093016 · Cited by 7 · see citing works
New Drug Research and Development for Alzheimer's Pathology: Present and Prospect.
Wang, T. (2017) · PubMed · doi:10.11919/j.issn.1002-0829.217045 · Cited by 6 · see citing works
Karur, P., Kaldas, M., Babu, Y. S. R., & Parmar, M. S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05647-1 · Cited by 5 · see citing works
A Global Review on Alzheimer’s Disease
Natarajan., P., Mumthaj., P., Vijay., J., & Gokul., V. (2021) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2021.v68i01.017 · Cited by 2 · see citing works
What to make of equivocal amyloid imaging results
Burrell, J. R., Foxe, D., Leyton, C. E., Piguet, O., & Hodges, J. R. (2020) · Neurocase · doi:10.1080/13554794.2020.1764056 · Cited by 2 · see citing works
Large Clinical Trials and Registries—Clinical Research Institutes
Califf, R. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-849905-4.00028-9 · Cited by 5 · see citing works
Qiu, Y.-H., Liu, M., Zhan, J., Liu, L., Zheng, J., Wu, D., Wu, G., Cai, Y., & Zhang, S. (2023) · medRxiv · doi:10.1101/2023.11.20.23298794 · Cited by 2 · see citing works
Can the entorhinal cortex help distinguish healthy aging brains from pathological aging brains?
Takashima, A., Koike, R., & Soeda, Y. (2022) · Aging Brain · doi:10.1016/j.nbas.2021.100026 · Cited by 1 · see citing works
“terms of inhibiting the progression of dementia [18,14,58,56,7,16,27].”
BackgroundPeng, D., Xu, S., Zou, T., Wang, Y., Ouyang, W., Zhang, Y., Dong, C., Li, D., Guo, J., Shen, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24630451
Peng, D., Xu, S., Zou, T., Wang, Y., Ouyang, W., Zhang, Y., Dong, C., Li, D., Guo, J., Shen, Q., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24630304
Antibody-Based Medicines Versus Conventional Treatments for Alzheimer’s Disease
Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_13
- Authors
- Neurology, T. L.
- Corresponding author
- The Lancet Neurology
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 16
- Issue
- 2
- Pages
- 97
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W4248280011
- Cited by
- 58
- References
- 0
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 7 · 2022: 2 · 2021: 7 · 2020: 7 · 2019: 7 · 2018: 7 · 2017: 13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, mild Alzheimer's disease, anti-amyloid therapy, amyloid-beta, disease progression, clinical trial design, treatment timing
- MeSH terms
- Alzheimer Disease, Drug Administration Schedule, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
